((R)-3-Methyl-1-((S)-3-phenyl-2-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)propanamido)butyl)boronic acid
95%
- Product Code: 229038
CAS:
1194235-41-0
| Molecular Weight: | 531.4 g./mol | Molecular Formula: | C₂₈H₃₄BN₅O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C |
Product Description:
Used primarily as a potent proteasome inhibitor, this compound plays a key role in the treatment of multiple myeloma and other hematologic cancers. It functions by reversibly inhibiting the chymotrypsin-like activity of the 20S proteasome, disrupting protein degradation in cells and leading to apoptosis, particularly in cancer cells with high protein turnover. Due to its stereospecific structure, it exhibits enhanced selectivity and potency compared to earlier boronic acid-based inhibitors. It is administered intravenously and has shown efficacy in patients who are refractory to other therapies. Its application is mainly in clinical oncology, often as part of combination regimens involving dexamethasone or immunomodulatory drugs.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 25mg | 10-20 days | ฿240,000.00 |
+
-
|
((R)-3-Methyl-1-((S)-3-phenyl-2-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)propanamido)butyl)boronic acid
Used primarily as a potent proteasome inhibitor, this compound plays a key role in the treatment of multiple myeloma and other hematologic cancers. It functions by reversibly inhibiting the chymotrypsin-like activity of the 20S proteasome, disrupting protein degradation in cells and leading to apoptosis, particularly in cancer cells with high protein turnover. Due to its stereospecific structure, it exhibits enhanced selectivity and potency compared to earlier boronic acid-based inhibitors. It is administered intravenously and has shown efficacy in patients who are refractory to other therapies. Its application is mainly in clinical oncology, often as part of combination regimens involving dexamethasone or immunomodulatory drugs.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :